Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

USA Capacity Utilization Rate for Jul 76.100% vs 75.700% Est; Prior 75.400%

USA Capacity Utilization Rate for Jul 76.100% vs 75.700% consensus estimate. The prior reading was 75.400%.

byBenzinga Newsdesk

August 17, 2021

1 minute read

USA Capacity Utilization Rate for Jul 76.100% vs 75.700% consensus estimate. The prior reading was 75.400%.

‘Elon Musk’s Tesla Now Hiring For Senior Roles In India’ -Earlier Bloomberg Report

By Benzinga Newsdesk

Today, 2:54 AM

https://www.ndtv.com/world-news/elon-musk-s-tesla-has-started-hiring-for-senior-roles-in-india-report-2455138?amp=1

TSLA

Abeona Therapeutics Says On March 3 CFO Edward Carr Notified Co Of His Resignation Effective March 31

By Benzinga Newsdesk

Today, 2:54 AM

-SEC Filing

ABEO

UBS Initiates Coverage On Ryan Specialty Group with Buy Rating, Announces Price Target of $36

By Benzinga Newsdesk

Today, 2:54 AM

UBS analyst Brian Meredith initiates coverage on Ryan Specialty Group (NYSE:RYAN) with a Buy rating and announces Price Target of $36.

RYAN

BMO Capital Downgrades CytomX Therapeutics to Market Perform, Lowers Price Target to $2.6

By Benzinga Newsdesk

Today, 2:54 AM

BMO Capital analyst Etzer Darout downgrades CytomX Therapeutics (NASDAQ:CTMX) from Outperform to Market Perform and lowers the price target from $3 to $2.6.

CTMX

USA Capacity Utilization Rate for Jul 76.100% vs 75.700% Est; Prior 75.400%

Related Posts

‘Elon Musk’s Tesla Now Hiring For Senior Roles In India’ -Earlier Bloomberg Report

Abeona Therapeutics Says On March 3 CFO Edward Carr Notified Co Of His Resignation Effective March 31

UBS Initiates Coverage On Ryan Specialty Group with Buy Rating, Announces Price Target of $36

BMO Capital Downgrades CytomX Therapeutics to Market Perform, Lowers Price Target to $2.6